IT
ITGDF.US Integral Diagnostics Limited
- Market cap
- USD 976M
- P/E
- 65.3x
- P/B
- 2.06x
- ROE
- 3.2%
- Dividend yield
- 2.47%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is ITGDF.US undervalued?
Graham numberITGDF.US trades 144.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Integral Diagnostics Limited fundamental analysis
No fundamental analysis for Integral Diagnostics Limited yet.
Integral Diagnostics Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Integral Diagnostics Limited
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, allied health professionals, and patients in Australia and New Zealand. It offers medical diagnostic imaging services, such as magnetic resonance imaging, computed tomography, mammography, ultrasound, and radiography, as well as nuclear medicine, including positron emission tomography. The company was founded in 1967 and is headquar…
Full company profileIntegral Diagnostics Limited financial statements
Integral Diagnostics Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 231M | 274M | 349M | 359M | 440M | 470M | 627M | 789M |
| Gross Profit | 221M | 262M | 332M | 340M | 419M | 447M | 599M | 753M |
| Operating Income | 36.5M | 47.2M | 54.2M | 36.4M | 39.1M | 42.2M | 57.5M | 68.4M |
| EBITDA | 50.3M | 69.5M | 89.0M | 69.7M | 92.5M | 6.73M | 87.7M | 127M |
| Net Income | 21.0M | 23.0M | 31.3M | 14.6M | 25.0M | -60.7M | 4.67M | 21.9M |
| EPS | 0.13 | 0.12 | 0.16 | 0.06 | 0.11 | -0.26 | 0.01 | 0.06 |
| Balance Sheet | ||||||||
| Total Assets | 315M | 580M | 655M | 783M | 839M | 744M | 1.43B | 1.43B |
| Total Liabilities | 187M | 352M | 400M | 436M | 466M | 443M | 733M | 746M |
| Shareholders' Equity | 127M | 228M | 255M | 347M | 373M | 302M | 694M | 676M |
| Cash & Short-term Investments | 21.0M | 58.0M | 62.2M | 123M | 33.9M | 42.4M | 52.1M | 51.3M |
| Cash Flow | ||||||||
| Capital Expenditure | 18.7M | 25.9M | 20.3M | 27.8M | 44.0M | 23.9M | 59.8M | 49.6M |
| Free Cash Flow | 15.3M | 28.4M | 49.3M | 9.33M | 27.4M | 42.3M | 14.0M | 45.6M |
| Ratios | ||||||||
| ROE | 16.5% | 10.1% | 12.3% | 4.2% | 6.7% | -20.1% | 0.7% | 3.2% |
| ROA | 6.7% | 4.0% | 4.8% | 1.9% | 3.0% | -8.2% | 0.3% | 1.5% |
| Net Profit Margin | 9.1% | 8.4% | 9.0% | 4.1% | 5.7% | -12.9% | 0.7% | 2.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Integral Diagnostics Limited dividends
- Dividend yield
- 2.47%
- Forward dividend
- 0.06 USD
- Payout ratio
- 118.2%
- Ex-dividend date
- Aug 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | AUD 25.9M | 0.07 | 118.2% |
| 2025 | AUD 15.5M | 0.04 | 330.8% |
| 2024 | AUD 13.8M | 0.06 | - |
| 2023 | AUD 12.6M | 0.05 | 50.5% |
| 2022 | AUD 20.9M | 0.09 | 142.9% |
| 2021 | AUD 17.9M | 0.09 | 57.2% |
| 2020 | USD 18.0M | 0.09 | 78.3% |
| 2019 | AUD 14.0M | 0.09 | 66.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Integral Diagnostics Limited
- Insiders 4.92%
- Institutions 51.10%
- Public & others 43.98%
- Shares outstanding 374M
- Free float 339M
Integral Diagnostics Limited company profile
- Company name
- Integral Diagnostics Limited
- Ticker
- ITGDF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,049
- Fiscal year end
- June
- Address
- 288 Victoria Parade, East Melbourne, VIC, Australia, 3002
- Phone
- 61 3 5339 0704
- Website
- integraldiagnostics.com.au
About Integral Diagnostics Limited
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, allied health professionals, and patients in Australia and New Zealand. It offers medical diagnostic imaging services, such as magnetic resonance imaging, computed tomography, mammography, ultrasound, and radiography, as well as nuclear medicine, including positron emission tomography. The company was founded in 1967 and is headquartered in East Melbourne, Australia.
Integral Diagnostics Limited management
6- Mr. Jason Martinez B.Com.MD, CEO & Director
- Ms. Jennifer Margaret Martin B.Acc ACAChief Financial Officer
- Mr. Julian GullyChief Information Officer
- Ms. Melissa WongChief People Officer
- Dr. Tony ChenChief Medical Officer
- Mr. John Merity B.A., L.L.B.Company Secretary